Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

Home / Blog / Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds
Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds
May 09, 2020May 9, 2020
0

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated with Yervoy (ipilimumab), a Phase 2 trial shows. These findings demonstrate that a subset of men with this form of advanced prostate cancer may benefit from treatment with immune checkpoint inhibitors — therapies that remove the “brakes” on the immune system to better fight cancer — despite having a low number of…

You must be logged in to read/download the full post.